Bacteriocins and postbiotics as anticancer agents: narrative review of mechanisms and translational opportunities
Narrative review indicates that microbiome-derived bacteriocins and postbiotic metabolites exert anticancer effects in preclinical models, but direct clinical evidence is absent — favorable direction is restricted to experimental contexts only.
| Population | No defined human population; preclinical studies (in vitro and animal models) and computational analyses |
|---|---|
| Intervention | Microbiome-derived bacteriocins and postbiotic metabolites (SCFAs, indole derivatives, reuterin, microbial exopolysaccharides) |
| Comparator | No standardized comparator; most primary studies use untreated tumor cells or vehicle |
| Outcome | Tumor cell viability (apoptosis/cell death); Inhibition of cell proliferation; Suppression of angiogenesis and metastasis; Antitumor immune modulation; Stability and bioavailability with nanotechnology; Clinical safety and pharmacokinetics in humans; Clinical efficacy in oncology patients |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Tumor cell viability (apoptosis/cell death) | not reported; preclinical only, in the pooled effect size | — | Very low | — | |
| Inhibition of cell proliferation | not reported; preclinical only, in the pooled effect size | — | Very low | — | |
| Suppression of angiogenesis and metastasis | not reported; preclinical only, in the pooled effect size | — | Very low | — | |
| Antitumor immune modulation | not reported; preclinical only, in the pooled effect size | — | Very low | — | |
| Stability and bioavailability with nanotechnology | not reported; preclinical only, in the pooled effect size | — | Very low | — | |
| Clinical safety and pharmacokinetics in humans | not reported; in the human data available | — | Very low | — | |
| Clinical efficacy in oncology patients | not reported; in the clinical trials exist | — | Very low | — |
Context
Bacteriocins are antimicrobial peptides produced by bacteria with selective cytotoxic activity demonstrated in tumor cell lines in vitro and animal models. Clinical interest grows as resistance to conventional chemotherapeutics increases. The absence of randomized clinical trials severely limits any direct therapeutic inference.
What the study showed
Bacteriocins demonstrated anticancer activity in vitro and in vivo through membrane disruption, apoptosis induction, proliferation inhibition, and angiogenesis/metastasis suppression, alongside epigenetic and immune modulation. SCFAs, indole derivatives, reuterin, and exopolysaccharides also showed tumor suppression in experimental models. Nanotechnology-based delivery systems improved compound stability and bioavailability in preclinical models. No consolidated numerical data (95% CI, effect sizes, patient numbers) were reported for clinical outcomes, as the review did not perform meta-analysis.
How it was done
Narrative review (non-systematic, without registered PRISMA protocol) of available literature on bacteriocins and postbiotics in oncology. No structured data extraction, formal risk-of-bias assessment (RoB 2, ROBINS-I, or AMSTAR-2), or quantitative synthesis was performed. Duration of included primary studies was not standardized.
Effect magnitude
No consolidated effect size was calculated. The review provides no 95% CI, RR, OR, or SMD for any outcome — effect magnitude is descriptive and derived from heterogeneous, unquantified studies.
Risk of bias
Narrative design without systematic methodology precludes formal risk-of-bias assessment (AMSTAR-2 not applicable due to absence of systematic criteria). No randomized clinical trials or prospective cohorts on bacteriocins in human oncology exist. Extreme heterogeneity of experimental models, cell lines, and compounds evaluated prevents generalization. Clinical evidence is virtually nonexistent.
What this study does NOT prove
This study does not prove anticancer efficacy in humans — all data are preclinical or computational. It does not demonstrate safety, therapeutic dose, systemic bioavailability, or clinical benefit in any patient population.
In clinical practice
There is no support for clinical use of bacteriocins or postbiotics as anticancer agents in oncology patients based on this review. Health professionals must not extrapolate preclinical findings to therapeutic decisions. The study serves as a hypothesis map for basic and translational research.
Limitations
Narrative design without systematic methodology precludes formal risk-of-bias assessment (AMSTAR-2 not applicable due to absence of systematic criteria). No randomized clinical trials or prospective cohorts on bacteriocins in human oncology exist. Extreme heterogeneity of experimental models, cell lines, and compounds evaluated prevents generalization. Clinical evidence is virtually nonexistent.
What is still missing
Phase I/II clinical trials evaluating safety, pharmacokinetics, and efficacy of purified or nano-formulated bacteriocins in oncology patients. Standardization of experimental methodologies and purity/production criteria are prerequisites.
Technical appendix
Version history
- 1.0 · 2026-10-24 — Auto-generated under Evidence Standard v1.0